<DOC>
	<DOCNO>NCT02983539</DOCNO>
	<brief_summary>The sarcomas represent 1 % cancer adult , 8 % adolescent young people , 10 % child . Even though rare cancer , contribute significant loss year life comparison type cancer , due fact affect child young people . The diagnosis treatment difficult , consider diversity rarity disease . In addition , average , 50 % patient high-grade sarcoma present tumor relapse distant recurrence consider main cause death . The presence Circulating Tumor Cells ( CTCs ) blood patient sarcoma may early marker tumor invasion , know CTCs circulate blood month year development metastasis . The CTCs use monitor response tumor treatment , order match time , dose , type therapy . Objectives : collect blood patient different type sarcoma ( leiomyosarcoma , synovial sarcoma , pleomorphic sarcoma liposarcoma ) order isolate quantify CTCs . The investigator also intention identify gene resistance treatment cell .</brief_summary>
	<brief_title>Detection Circulating Tumor Cells Patients With Sarcomas</brief_title>
	<detailed_description>Methodology : This prospective study , make whole blood collection 40 patient different type sarcoma ( leiomyosarcoma , pleomorphic sarcoma , synovial sarcoma liposarcoma ) . The collection make three different moment : beginning treatment , end ( 8 mL ) . Blood sample process filter ISET system isolation quantification CTCs . Later , perform immunocytochemistry ( ICQ ) single and/or double stain protein assessment . The following protein assess : CD45 , MRP1 , MRP2 MRP7 . Expected Results : The investigator hope study show CTCs use `` liquid biopsy '' patient leiomyosarcoma , synovium pleomorphic sarcoma liposarcoma .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Neoplastic Cells , Circulating</mesh_term>
	<mesh_term>Leiomyosarcoma</mesh_term>
	<mesh_term>Liposarcoma</mesh_term>
	<mesh_term>Sarcoma , Synovial</mesh_term>
	<criteria>18 year ; type sarcoma : leiomyosarcoma , pleomorphic sarcoma , synovial sarcoma liposarcoma . extension disease determine physical examination imaging ; measurable disease RECIST criterion ( Response Evaluation Criteria Solid Tumors ) ; patient undergo previous therapy last three week ; patient history cancer past two year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>sarcoma</keyword>
	<keyword>immunocytochemistry</keyword>
	<keyword>circulate tumor cell</keyword>
</DOC>